Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial

ConclusionWhile the difference between site and central PFS dates was statistically significant, the 0.3‐month median difference is small. The variability within central review is consistent with previous studies, highlighting the challenges in MRI interpretation in this context. A small proportion of patients benefited from treatment well beyond the centrally determined progression date, reinforcing that clinical status together with radiology results are important determinants of whether a therapy is effective for an individual.

Source: Asia-Pacific Journal of Clinical Oncology - November 8, 2017 Category: Cancer & Oncology Authors: Kathryn M. Field, Greg Fitt, Mark A. Rosenthal, John Simes, Anna K. Nowak, Elizabeth H. Barnes, Kate Sawkins, Christine Goh, Bradford A. Moffat, Simon Salinas, Lawrence Cher, Helen Wheeler, Elizabeth J. Hovey, Pramit M. Phal, Tags: ORIGINAL ARTICLE Source Type: research